Physician profile
Sangjin Lee
NPI 1013050764
$24,526.13
in general payments reported to CMS, 2019-2025
20 companies · $923 in 2025
The $923 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,787 · 2020: $331 · 2021: $2,669 · 2022: $1,248 · 2023: $9,115 · 2024: $453 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,250 · Travel and Lodging: $3,281 · Food and Beverage: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,250.00 |
| Travel and Lodging | $3,281.21 |
| Food and Beverage | $2,959.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14,551.36 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Medtronic Vascular, INC. | $6,014.28 | 2019-2020 | |
| Ancora Heart, INC. | $2,133.29 | 2021-2024 | Accucinch |
| Cvrx, INC. | $446.66 | 2023-2025 | Barostim Neo System |
| Pfizer INC. | $258.97 | 2019-2025 | |
| Abiomed | $219.87 | 2024-2025 | Impella |
| Medtronic, INC. | $154.12 | 2021-2025 | Micra |
| Astrazeneca Pharmaceuticals LP | $147.26 | 2021-2025 | Wainua, Farxiga |
| Edwards Lifesciences Corporation | $135.47 | 2023 | Pascal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.18 | 2019-2022 | |
| Livanova USA, INC. | $78.80 | 2023 | Tandemheart |
| Novartis Pharmaceuticals Corporation | $57.49 | 2019-2023 | |
| Atricure, INC. | $42.18 | 2024 | |
| Merck Sharp & Dohme LLC | $34.60 | 2021-2022 | |
| Chiesi USA, INC. | $31.02 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22.29 | 2019 | |
| Janssen Biotech, INC. | $21.30 | 2024 | Tremfya |
| Impulse Dynamics (USA) INC. | $17.76 | 2025 | Optimizer |
| Amgen INC. | $16.65 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sangjin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.